Tetra Bio Pharma (CVE:TBD- TBPMF:OTCMKTS) Robert Béchard , Executive Vice President, Corporate Development and Licensing joined Steve Darling from Proactive Investors to talk about his company that is billed as a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma ready to lead in cannabinoid drug development
Quick facts: Tetra Bio-Pharma
Price: 0.2 CAD
Market Cap: $56.37 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE